Transcriptional changes underlying the secretory activation phase of mammary gland development.
The secretory activation stage of mammary gland development occurs after parturition and converts inactive lobuloalveoli to active milk secretion. This process is triggered by progestin withdrawal and depends upon augmented prolactin (Prl) signaling. Little is known about the Prl-induced transcriptional changes that occur in the mammary gland to drive this process. To examine changes in the mammary transcriptome responsible for secretory activation, we have used transcript profiling of three mouse models that exhibit failure of secretory activation: knockout of galanin (a regulator of pituitary Prl production and a mammary cell autonomous modulator of Prl action); treatment with S179D Prl (a phosphoprolactin mimic); and knockout of a single Prl receptor allele. A significant reduction in expression was observed in genes belonging to 46 gene ontologies including those representing milk proteins, metabolism, lipid, cholesterol and fatty acid biosynthetic enzymes, immune response, and key transcription factors. A set of 35 genes, commonly regulated in all three models, was identified and their role in lactogenesis was validated by examining their expression in response to Prl stimulation or signal transducer and activator of transcription 5 knockdown in the HC11 mouse mammary cell culture model. The transcript profiles provided by these experiments identify 35 key genes (many for the first time) involved in the secretory activation phase of mammary gland development, show that S179D acts as an antagonist of Prl action, and provide insight into the partial penetrance of failed lactation in Prl receptor heterozygous females.
Naylor
Matthew J
MJ
Development Group, Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, New South Wales 2010, Australia.
Oakes
Samantha R
SR
Gardiner-Garden
Margaret
M
Harris
Jessica
J
Blazek
Katrina
K
Ho
Timothy W C
TW
Li
Foo C
FC
Wynick
David
D
Walker
Ameae M
AM
Ormandy
Christopher J
CJ
D000483:Alleles; D000818:Animals; D002478:Cells, Cultured; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005260:Female; D019004:Galanin / Q000235:genetics; D020869:Gene Expression Profiling; D007774:Lactation / Q000235:genetics*; D008055:Lipids / Q000096:biosynthesis; D008321:Mammary Glands, Animal / Q000033:anatomy & histology / Q000254:growth & development* / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D008894:Milk Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009154:Mutation; D020411:Oligonucleotide Array Sequence Analysis; D010766:Phosphorylation; D011388:Prolactin / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D014176:Protein Biosynthesis / Q000235:genetics; D050799:STAT5 Transcription Factor; D015534:Trans-Activators / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014158:Transcription, Genetic
D004268:DNA-Binding Proteins; D008055:Lipids; D008894:Milk Proteins; D050799:STAT5 Transcription Factor; D015534:Trans-Activators; C422171:prolactin, Asp(179)-; D019004:Galanin; D011388:Prolactin